Single doses of up to 1750mg of bebtelovimab (10 times the authorized dose) have been administered in clinical trials without evidence of dose-limited toxicity. Treatment of bebtelovimab overdose should consist of general supportive measures.L40288
Bebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. It binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells. Bebtelovimab is notable in that the epitope to which it binds appears infrequently mutated, making it a viable candidate for use in resistant SARS-CoV-2 strains (i.e. variants of concern, VOCs), including the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants.A245353 This is in contrast to previously developed COVID-19 monoclonal antibody treatments - including bamlanivimab, etesevimab, casirivimab, and imdevimab - which have been found ineffective in the treatment of COVID-19 caused by the Omicron variant.L40328
Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.L40313 In November 2022, the FDA updated the Health Care Provider Fact Sheet for bebtelovimab to inform of its expected reduced activity against certain emerging Omicron subvariants of SARS-CoV-2.L43827 On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use in the US.L44241
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Bebtelovimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Bebtelovimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Bebtelovimab. |
| Estrone | Estrone may increase the thrombogenic activities of Bebtelovimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Bebtelovimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Bebtelovimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Bebtelovimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Bebtelovimab. |
| Estriol | Estriol may increase the thrombogenic activities of Bebtelovimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Bebtelovimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Bebtelovimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Bebtelovimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Bebtelovimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bebtelovimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bebtelovimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Bebtelovimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Bebtelovimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Bebtelovimab. |
| Equol | Equol may increase the thrombogenic activities of Bebtelovimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Bebtelovimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Bebtelovimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Bebtelovimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Bebtelovimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Bebtelovimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Bebtelovimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Bebtelovimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Bebtelovimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Bebtelovimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Bebtelovimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Bebtelovimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Bebtelovimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bebtelovimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Bebtelovimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Bebtelovimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Bebtelovimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bebtelovimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bebtelovimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Bebtelovimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bebtelovimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bebtelovimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bebtelovimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bebtelovimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bebtelovimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bebtelovimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Bebtelovimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bebtelovimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bebtelovimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bebtelovimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bebtelovimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Bebtelovimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bebtelovimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bebtelovimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bebtelovimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bebtelovimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Bebtelovimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Bebtelovimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bebtelovimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Bebtelovimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bebtelovimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Bebtelovimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bebtelovimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Bebtelovimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Bebtelovimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Bebtelovimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Bebtelovimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Bebtelovimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Bebtelovimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Bebtelovimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Bebtelovimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Bebtelovimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Bebtelovimab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Bebtelovimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Bebtelovimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Bebtelovimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Bebtelovimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Bebtelovimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Bebtelovimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Bebtelovimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Bebtelovimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Bebtelovimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Bebtelovimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Bebtelovimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Bebtelovimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Bebtelovimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bebtelovimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Bebtelovimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Bebtelovimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Bebtelovimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bebtelovimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Bebtelovimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Bebtelovimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Bebtelovimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Bebtelovimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Bebtelovimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Bebtelovimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Bebtelovimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Bebtelovimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bebtelovimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Bebtelovimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Bebtelovimab. |